SAL003 140 mg + Placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemias
Conditions
Hyperlipidemias
Trial Timeline
Oct 23, 2023 โ May 8, 2025
NCT ID
NCT07295418About SAL003 140 mg + Placebo
SAL003 140 mg + Placebo is a phase 3 stage product being developed by Shenzhen Salubris Pharmaceuticals for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT07295418. Target conditions include Hyperlipidemias.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07253584 | Phase 3 | Completed |
| NCT07295418 | Phase 3 | Completed |
Competing Products
5 competing products in Hyperlipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Evolocumab + Statins (Cardiovascular Agents) | Amgen | Approved | 84 |
| atorvastatin + atorvastatin + atorvastatin | Pfizer | Approved | 84 |
| SAL003 140 mg + Placebo | Shenzhen Salubris Pharmaceuticals | Phase 3 | 76 |
| SLN360 + Placebo | Medpace | Phase 1 | 30 |
| Bempedoic Acid + Ezetimibe + Placebos | Esperion Therapeutics | Phase 3 | 72 |